Yazar "Idilman, Ramazan" seçeneğine göre listele

Listeleniyor 1 - 5 / 5
  • [ X ]
    Öğe
    THE BURDEN OF DELTA HEPATITIS PROJECTED USING A MATHEMATICAL MODEL IN A DELTA HEPATITIS ENDEMIC COUNTRY
    (John Wiley & Sons Inc, 2009) Toy, Mehlika; Onder, Fatih Oguz; Idilman, Ramazan; Bozkaya, Hakan; Degertekin, Halil; Yalcin, Kendal; Schalm, Solko W.
    [Abstract Not Available]
  • [ X ]
    Öğe
    Can response to pegylated interferon treatment in chronic delta hepatitis be predicted with on-treatment parameters?
    (Wiley-Blackwell, 2012) Onder, Fatih Oguz; Erhardt, Andreas; Idilman, Ramazan; Keskin, Onur; Dalekos, George N.; Yalcin, Kendal; Manns, Michael P.
    [Abstract Not Available]
  • [ X ]
    Öğe
    A one step real time PCR method for the quantification of hepatitis delta virus RNA using an external armored RNA standard and intrinsic internal control
    (Elsevier Science Bv, 2014) Karatayli, Ersin; Altunoglu, Yasemin Celik; Karatayli, Senem Ceren; Alagoz, S. Gokce K.; Cinar, Kubilay; Yalcin, Kendal; Idilman, Ramazan
    Background: Hepatitis delta virus (HDV) RNA viral load measurement is critical in diagnosis and monitoring the response to antiviral treatment. Objectives: Our aim is to design a real time PCR method for accurate quantitation of HDV RNA in clinical specimens using an armored RNA as external standard, and an intrinsic internal control. Study design: A plasmid bearing delta antigen region of genotype I HDV genome was used to develop an armored RNA. Serial dilutions of the armored HDV RNA standard with 10(12) copy/mL were used as standards for quantitation. A primer-probe set derived from HDAg region was used in one step EZ RT PCR kit chemistry which uses rTth enzyme allowing reverse transcription and polymerization in the same tube. The kit also uses the advantage of uracil-N-glycosylase (UNG) enzyme treatment to prevent PCR contamination. Results: The established assay has a dynamic range of 10(2)-10(11) copy/mL with a PCR efficiency of 96.9%. Detection limit was 858 +/- 32 copy/mL with 95% confidence interval. Intra-and inter-assay variabilities were low for high, medium and low levels of viremia. Incorporation of freely circulating GAPDH in serum into the assay as an intrinsic internal control prevented false negative results and failures in PCR amplifications due to inhibitors, inefficient extraction procedures or enzymatic reactions. Conclusion: In conclusion, this study defines a novel assay for sensitive and reliable quantification of HDV RNA using an armored HDV RNA as a standard and GAPDH in plasma or serum as an intrinsic internal control in a single tube. (c) 2014 Elsevier B.V. All rights reserved.
  • [ X ]
    Öğe
    Potential role of cytokine gene polymorphisms in outcome of chronic delta hepatitis
    (John Wiley & Sons Inc, 2006) Ulger, Zeynep; Emir, Filiz; Arslan-Ergul, Ayca; Idilman, Ramazan; Yalcin, Kendal; Uzunalimoglu, Oezden; Bozkaya, Hakan
    [Abstract Not Available]
  • Küçük Resim
    Öğe
    Residual low HDV viraemia is associated HDV RNA relapse after PEG-IFNa-based antiviral treatment of hepatitis delta: Results from the HIDIT-II study
    (Wiley, 2020) Bremer, Birgit; Anastasiou, Olympia E.; Hardtke, Svenja; Caruntu, Florin Alexandru; Curescu, Manuela G.; Yalçın, Kendal; Akarca, Ulus S.; Gürel, Selim; Zeuzem, Stefan; Erhardt, Andreas; Luth, Stefan; Papatheodoridis, George, V.; Radu, Monica; Idilman, Ramazan; Manns, Michael P.; Cornberg, Markus; Yurdaydın, Cihan; Wedemeyer, Heiner
    The role of low levels of HDV-RNA during and after interferon therapy of hepatitis D is unknown. We re-analysed HDV RNA in 372 samples collected in the HIDIT-2 trial (Wedemeyer et al, Lancet Infectious Diseases 2019) with the Robogene assay (RA; Jena Analytics). Data were compared with the previously reported in-house assay (IA). We detected HDV-RNA in one-third of samples previously classified as undetectable using the highly sensitive RA. Low HDV viraemia detectable at week 48 or week 96 was associated with a high risk for post-treatment relapse, defined as HDV RNA positivity in both assays at week 120. HDV RNA relapses occurred in 10/15 (67%) patients with detectable low HDV RNA at week 48 and in 10/13 (77%) patients with low viraemia samples at week 96. In contrast, the post-treatment relapse rate was lower in patients with undetectable HDV RNA in both assays during treatment.